Clinical Trial Search

Primary: Percentage of Patients Without Loss of Systemic Lupus Erythematosus Disease Activity Improvement on Day 225 — 21; 12 Participants — p=0.1830

Primary: Number of the Patients That Achieve Higher Tolerance of Allergen With Immunotherapy — 6; 4; 3 participants

Primary: Subjects in Which the SLN(s) Are Identified — 27 Participants

Primary: Number of Participants With Clinically Significant Effects — 0; 1; 0; 0 Participants

Primary: Change From Baseline in the Total Nasal Symptom Score (TNSS) (Average of Morning [AM]/Evening [PM] Score) Averaged Over Days 1 to 15 (Participant-Evaluated) — 7.6; 7.3…

Primary: Part A: Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs in Cohort 1 — 0; 1; 0; 0 Participants

Primary: Change in Number of Cellphone Unlocks Per Hour of Drive Time — 0.81; 3.61 Cell phone unlocks per hour

Primary: Referral Rates to Local Hospitals — 33; 20; 31; 34 Referrals per 100 births

Primary: Change in Body Weight at 12 Months — -1.2; -1.9; -3.1 kilograms — p=0.00017

Primary: Apnea Hypopnea Index (AHI) — 50.0; 51.8 events/hour — p=0.576

Primary: Total Number of Serrated Lesions Proximal to the Sigmoid Colon — 204; 158; 95; 59 Serrated Lesions

Primary: Percentage of Participants Who Reported 1 or More Adverse Event (AE) - Healthy Participants — 100.0; 100.0; 80.0; 33.3 Percentage of Participants

Primary: Number of Participants With 1 or More Serious Adverse Event(s) (SAEs) — 0; 0; 0; 0 Participants

Primary: Dose Escalation Phase: Maximum Tolerated Dose (MTD) — 8 mg (QD×3d QW)

Primary: K-max — -0.52; -0.82 Diopters (D) — p=<0.05